Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy:: IMPROVE™ study subgroup analysis

被引：0
|
作者：
Kawamori, R. [1 ]
Srishyla, M. V. [2 ]
Wenying, Y. [3 ]
机构：
[1] Juntendo Univ, Sch Med, Dept Metab & Endocrinol, Tokyo 113, Japan
[2] Novo Nordisk AS, Virum, Denmark
[3] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
978
引用
收藏
页码：S393 / S394
页数：2
相关论文
共 50 条
  • [1] Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naive Patients with Type 2 Diabetes
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    Aminorroaya, Ashraf
    Aboutorabi, Robabeh
    Niafar, Mitra
    Mohammadi, Mohammad
    Parvaresh, Ehsan
    JOURNAL OF DIABETES & METABOLISM, 2011, 2 (03)
  • [2] Improved glycemic control with NovoMix® 30 (BIAsp 30) in insulin-naive patients with type 2 diabetes:: Subgroup analysis from the IMPROVE™ study
    Gumprecht, Janusz
    Hansen, Jes B.
    Borzi, Vito
    DIABETES, 2008, 57 : A577 - A577
  • [3] Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
    Gumprecht, J.
    Benroubi, M.
    Borzi, V.
    Kawamori, R.
    Shaban, J.
    Shah, S.
    Shestakova, M.
    Wenying, Y.
    Ligthelm, R.
    Valensi, P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 966 - 972
  • [4] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
    Valensi, Paul
    DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71
  • [5] Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study
    Yang Wenying
    Benroubi, Marian
    Borzi, Vito
    Gumprecht, Janusz
    Kawamori, Ryuzo
    Shaban, Joseph
    Shah, Siddharth
    Shestakova, Marina
    Ligthelm, Robert
    Valensi, Paul
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2643 - 2654
  • [6] Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan
    Ishii, Hitoshi
    Iwase, Masanori
    Seino, Hiroaki
    Shuto, Yujin
    Atsumi, Yoshihito
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 643 - 650
  • [7] Improved Safety and Efficacy Profile in Patients with Type 2 Diabetes Treated with Biphasic Insulin Aspart 30 (BIAsp 30): Iran Subgroup of the IMPROVE Study
    Esteghamati, Alireza
    Rajabian, Reza
    Amini, Masoud
    Bahrami, Amir
    Khamseh, Mohammad Ebrahim
    Ardekani, Mohammad Afkhami
    Rizi, Ehsan Parvaresh
    DIABETES, 2009, 58 : A527 - A527
  • [8] Biphasic Insulin Aspart 30 as Initiation Therapy in Chinese Insulin-Naive Subjects with Inadequately Controlled Type 2 Diabetes-IMPROVE™ China Subgroup Data
    Gao, Yan
    Yang, Wenying
    Liu, Guoliang
    Chen, Lulu
    Fu, Zuzhi
    Zou, Dajin
    Feng, Ping
    Zhao, Zhigang
    DIABETES, 2009, 58 : A516 - A517
  • [9] GLYCAEMIC CONTROL AND INSULIN UTILIZATION IN UK PATIENTS WITH TYPE 2 DIABETES INITIATED ON EITHER BIPHASIC INSULIN ASPART 30 OR BIPHASIC HUMAN INSULIN 30
    Fakhoury, W.
    Richter, H.
    Christensen, T.
    Thomsen, T. L.
    Irwin, D.
    Anderson, P.
    VALUE IN HEALTH, 2010, 13 (03) : A55 - A55
  • [10] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    DIABETES, 2014, 63 : A225 - A225
12345